BIORA THERAPEUTICS INC (BIOR) Stock News
NASDAQ:BIOR - Nasdaq - US74319F3055 - Common Stock
BIOR Latest News and Analysis
Biora Therapeutics Undertakes Chapter 11 Sale Process to Position Business for Future Growth
Biora Therapeutics Undertakes Chapter 11 Sale Process to Position Business for Future Growth
Sale process will help enable next stage of product development Secures up to $10.25 million in new financing to support ongoing business operations SAN...
Why Biora Therapeutics (BIOR) Stock Is Down 45%
Biora Therapeutics shares are trading lower by 45% during Tuesday's session. The company announced that it will be delisted from Nasdaq.
Biora Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results
Biora Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results
Testing in advanced animal model planned in Q4 for smaller, 00-size BioJet device with largest capacity of any ingestible injectable Company granted...
Biora Therapeutics to Report Third Quarter 2024 Financial Results and Provide Corporate Update
Biora Therapeutics to Report Third Quarter 2024 Financial Results and Provide Corporate Update
SAN DIEGO, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company reimagining therapeutic delivery, today...
Biora Therapeutics Announces $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Biora Therapeutics Announces $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
SAN DIEGO, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company reimagining therapeutic delivery, today...
Biora Therapeutics Shares Progress on Smaller BioJet™ Clinical Device with Largest Payload of any Ingestible Injectable at the 14th Annual PODD Meeting
Expanded collaborations to support rapid testing in advanced animal models in Q4 2024
Biora Therapeutics Shares Progress on Smaller BioJet™ Clinical Device with Largest Payload of any Ingestible Injectable at the 14th Annual PODD Meeting
Expanded collaborations to support rapid testing in advanced animal models in Q4 2024...
Biora Therapeutics to Reveal 00-Size BioJet™ Device at the 14th Annual Partnership Opportunities in Drug Delivery Meeting
Biora Therapeutics to Present at the 19th Annual Peptide Therapeutics Symposium
Biora Therapeutics to Present at the 19th Annual Peptide Therapeutics Symposium
SAN DIEGO, Oct. 07, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company reimagining therapeutic delivery, today...
Biora Therapeutics Announces Award-Winning Abstract to be Presented at American College of Gastroenterology Annual Scientific Meeting 2024
Biora Therapeutics Announces Award-Winning Abstract to be Presented at American College of Gastroenterology Annual Scientific Meeting 2024
SAN DIEGO, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company reimagining therapeutic delivery, today...
Biora Therapeutics Achieves ISO 13485 Certification
Underscoring the company’s commitment to quality and excellence
Biora Therapeutics Announces Positive Nasdaq Listing Decision
Company granted extension to regain compliance with Nasdaq listing requirements
Biora Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference
Biora Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference
SAN DIEGO, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company reimagining therapeutic delivery, today...
BIOR Stock Earnings: Biora Therapeutics Beats EPS for Q2 2024
BIOR stock results show that Biora Therapeutics beat analyst estimates for earnings per share the second quarter of 2024.
BIOR Stock Earnings: Biora Therapeutics Beats EPS for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Biora Therapeutics (NASDAQ:BIOR) just reported results for the second quarter o...
Biora Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results
Biora Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results
Phase 1 clinical trial results for BT-600 demonstrate precise drug delivery to the colon with low systemic exposure, supporting clinical development plan ...
Biora Therapeutics Announces Funding Agreement with Existing Investors
$16 million multiple-draw facility to be used as a bridge to anticipated pharma partnership
Biora Therapeutics Announces Funding Agreement with Existing Investors
$16 million multiple-draw facility to be used as a bridge to anticipated pharma partnership...
Biora Therapeutics to Report Second Quarter 2024 Financial Results and Provide Corporate Update
Biora Therapeutics to Report Second Quarter 2024 Financial Results and Provide Corporate Update
SAN DIEGO, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company reimagining therapeutic delivery, today...
Biora Therapeutics to Participate in Canaccord Genuity 44th Annual Growth Conference
Biora Therapeutics Announces Supplemental Data from Phase 1 Clinical Trial of BT-600 as Presented at KOL Event
Biora Therapeutics Announces Supplemental Data from Phase 1 Clinical Trial of BT-600 as Presented at KOL Event
Pharmacokinetic and tissue data confirm NaviCap platform delivers topically through the entire colon, with lower systemic concentrations, as desired....
Biora Therapeutics to Host Virtual KOL Event on NaviCap™ Targeted Oral Delivery Platform and Results from Phase 1 Clinical Trial of BT-600 on July 17, 2024